31 October 2019
Bowel Management Systems Market Forecast 2020-2030: Forecasts and Analysis By Product (Colostomy Bags, Irrigation Systems, Nerve Modulation Devices & Accessories (Radiofrequency, Surgical Implants, Artificial anal Sphincters, Anal Plugs, Colostomy Accessories), Patient Type (Adult and Pediatric), End User (Ambulatory Surgery Centres, Home Care and Hospitals) and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Bowel Management Systems sector analysis.
According to the report published by Visiongain, the Bowel Management Systems market is projected at USD 2.3 billion in 2020. During the 2020-2030 prediction era, it is probable to grow at a CAGR of 3.3%. Growing geriatric population, combined with growing bowel management consciousness, has stimulated market growth.
Because of the growing older workforce, together with the growing destination person demographic, the worldwide bowel leadership system industry has increased considerably. In addition, the development of the global industry drives rising creative item releases and favorable reimbursement scenarios in advanced nations. Some of the possibilities to boost development on this industry are the development of cheap bowel management schemes and bowel management reimbursement disruption in emerging countries. Injuiciation linked to the use of bowel management equipment and customer preferences to non-invasive fecal incontinence clinical leadership is however impeding the worldwide bowel management system industry. However, demonstrated technological advances could contribute to the future development of a stronger bowel management system.
Bowel Management Systems Market is witnessing Growth due to factors such as
Modern fecal incontinence leadership methods include devices specifically designed to divert fecal waste into collection bags, thereby reducing the soiling and spread of infectious micro-organisms and helping to preserve the integrity of the skin.3,8-10 One such device is the Flexi-Seal. Fecal Management System (FFMS) (Flexi-Seal is a registered trademark of ConvaTec Inc; ConvaTec, Inc, Skillman, NJ). The FFMS is a transitional fecal distraction and containment scheme consisting of a smooth elastic silicone pipe about 1.55 M lengthy with a smooth silicone catheter at one end embedded into the rectum of the patient and maintained by a low-pressure holding balloon.
This FFMS has been approved by the U.S. Food and Drug Administration and is indicated for fecal management in patients with little or no bowel control and liquid or semi-liquid stool; its use is contraindicated in pediatric patients for longer than 29 days and in situations where rectal tissue is compromised. A potential, single-arm FFMS clinical study10 registered 42 individuals with diarrhea and incontinence and surveyed 38 nurses who had been using FFMS for > 24 hours; among these 38 nurses, FFMS was found to be secure and efficient in fecal waste diversion. Of 39 who had basis and initial appointment hair assessments, 36 (92%) either retained or enhanced body consistency. Eight individuals received both standard and endoscopic follow-up proctoscopy showing rectal mucosa stayed safe, suggesting that placing FFMS in the rectum does not harm rectal mucosa, a prospective danger of any instrument. An evaluation of the FFMS by chosen institutions of the National Health Service in the UK also stated that, in 238 (98 percent) times, employee skin quality was preserved or enhanced from 243 studies pertaining to individual nurses in whom FFMS was used.
Shift in Trends
According to a study, An Aging World, a predicted 617.1 million or 8.5 percent of the world's 7.3 billion population were aged 65 or younger in 2015. The percentage of older individuals is probable to rise by more than 60% in just 15 years. Aging has become a significant fecal incontinence threat variable. In females, bowel incontinence happens in 6.0 half of those under the era of 40 and rises to 15.0 percent in elderly females, according to the International Foundation for Gastrointestinal Disorders. In addition, bowel incontinence happens in 6.0-10.0 ##fold among males and rises with era. In fact, technologically sophisticated products are being introduced to increase market growth. For example, the Biodesign program at Stanford University, Pelvalon, launched the Eclipse system-an innovative non-surgical treatment that provides instant results for women with bowel control loss.
According to the WHO, lives expectancy in most developed countries now exceeds 80 years. In geriatric populations, incontinence is associated with various variables that interact, including chronic diseases such as stroke and disease, loss of vision, and cognitive impairment. Fecal incontinence significantly affects a patient’s quality of life. Bowel management systems plays an important role in improving lifestyles of people suffering from the disorder and making their condition better.
Organizations like United Ostomy Associations of America, Inc., and United Kingdom. Colostomy. Work to empower people with ostomy. In addition, government agencies in advanced areas are introducing systems to assist people with a stoma by enhancing access to the most suitable stoma-related products that are clinically appropriate. These variables will also lead to the development of the section of colostomy sacks. The market was classified into colostomy sacks, irrigation structures, nerve modulation devices, and other products based on products. Due to increased consciousness of their accessibility and advantages, colostomy pads accounted for the biggest market share in 2019. In addition, the accessibility of well-structured colostomy product reimbursement policies across developed fields is anticipated to increase the sector over the forecast period.
The industry was divided into adult and pediatric based on the sort of person. The section of adults was the biggest in 2019. Significant development is anticipated over the forecast period. The elevated incidence of fecal incontinence among adolescents can be ascribed to this development. It is a prevalent adult disorder that affects about 1 in 12 adults or 18 million individuals in the U.S. Fecal incontinence is very prevalent and impacts about 10.0 half of the population, according to the BMJ Publishing Group. Increasing the accessibility of technologically sophisticated products also helps nurses to efficiently manage fecal incontinence, which is expected to boost the development of the general industry for intestinal leadership devices. In addition, increasing customer consciousness projects linked to efficient fecal incontinence therapy further accelerate this segment's development.
Furthermore, introduction of user-friendly products by manufacturers has enabled patients to maintain their independence and improve their quality of lives. The industry was segmented into home care and clinics and outpatient surgery centers based on end-use. In 2019, the home care sector was leading the industry. During the forecast period, it is probable to see the highest development. The segment's dominance can be ascribed to the increasing acceptance in home care environments of bowel management goods. In addition, producers ' implementation of user-friendly goods has allowed clients to keep their autonomy and enhance their standard of life. Technologically sophisticated goods have assisted nurses take charge of their bowel issues and proceed their daily practice with convenience. These variables complemented the development further.
Regional Market Analysis
North America, accompanied by Europe, was the biggest global industry in 2019. Because of the presence of significant market players such as 3 M and Medtronic, the former will proceed to dominate the worldwide industry until 2030. Higher bowel management schemes acceptance rates, combined with customer consciousness, well-established healthcare infrastructure, and elevated acceptance of sophisticated products are among the main variables promoting the region's dominance. Due to the growing incidence of fecal incontinence combined with growing geriatric population, Asia Pacific is expected to experience the highest development during the forecast period
Competition in the market
Players engage in various marketing strategies such as R&D operations, growing amount of partnerships, sensitivity programs, technological advances, regional extension, and fresh product launches to boost their business value. For example, in 2017, C.R was purchased by BD, a major medical technology firm. Bard with the goal of strengthening their business situation. The key players in the market are Medtronic; Coloplast; 3M; B. Braun; Consure Medical; C.R. Bard; Cogentix Medical; Axonics Modulation Technologies; Aquaflush Medical Limited; ConvaTec; MBH-International A/S; Hollister; Mederi Therapeutics Inc.; Wellspect HealthCare; and Welland Medical limited.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth